1. Home
  2. SN vs BIIB Comparison

SN vs BIIB Comparison

Compare SN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SharkNinja Inc.

SN

SharkNinja Inc.

HOLD

Current Price

$108.20

Market Cap

12.4B

Sector

N/A

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.52

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SN
BIIB
Founded
1993
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
SN
BIIB
Price
$108.20
$181.52
Analyst Decision
Strong Buy
Buy
Analyst Count
7
23
Target Price
$126.29
$176.48
AVG Volume (30 Days)
2.0M
1.9M
Earning Date
11-06-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
58.74
N/A
EPS
4.05
10.97
Revenue
$6,084,941,000.00
$10,065,900,000.00
Revenue This Year
$18.94
$3.61
Revenue Next Year
$11.59
N/A
P/E Ratio
$26.75
$16.52
Revenue Growth
18.87
4.77
52 Week Low
$60.50
$110.04
52 Week High
$128.51
$185.17

Technical Indicators

Market Signals
Indicator
SN
BIIB
Relative Strength Index (RSI) 70.08 72.92
Support Level $94.94 $174.53
Resistance Level $108.24 $182.94
Average True Range (ATR) 4.18 5.22
MACD 2.42 0.25
Stochastic Oscillator 98.42 83.54

Price Performance

Historical Comparison
SN
BIIB

About SN SharkNinja Inc.

SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: